Angiotech Looks Beyond Stents To Other Anti-Scarring Treatments
This article was originally published in The Gray Sheet
Executive Summary
Angiotech will begin studies evaluating paclitaxel for elbow and knee injuries in an effort to diversify its product offerings starting in the third quarter
You may also be interested in...
Combo Product Firms Should Follow Specialty Pharma Model – Angiotech
Angiotech Pharmaceuticals believes the best way to commercially exploit drug/device combination products is to act like a specialty pharmaceutical firm instead of a device company
Combo Product Firms Should Follow Specialty Pharma Model – Angiotech
Angiotech Pharmaceuticals believes the best way to commercially exploit drug/device combination products is to act like a specialty pharmaceutical firm instead of a device company
Combo Product Excitement: Large Players On Look-Out For Early-Stage Deals
Heightened corporate interest in innovative drug-delivery technologies offers greater opportunities for small device firms to attract larger company investment, venture capitalists say